<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374397</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1707</org_study_id>
    <nct_id>NCT03374397</nct_id>
  </id_info>
  <brief_title>PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy</brief_title>
  <acronym>PRAHA</acronym>
  <official_title>A Single Center, Randomized, Investigator-initiated Phase III Trial to Evaluate the Efficacy of Preservation of Ovarian Function and Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare hemostasis, ovarian function preservation effect, and
      safety about intraoperative bleeding with SurgiGuard@ in women who underwent laparoscopic
      unilateral ovarian cystectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women who underwent laparoscopic unilateral ovarian cystectomy, the effect of SurgiGuard@
      was assessed by randomization, using SurgiGuard@ and Bipolar electro cauterization, followed
      by comparative evaluation of hemostasis, ovarian function preservation, safety using
      postoperative Hb, anti-mullerian hormone (AMH), pelvis ultrasonography (USG), and physical
      examination
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemostasis</measure>
    <time_frame>post operative 48 hours later,1 week later, and 12 weeks later</time_frame>
    <description>Change of serum hemoglobin from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian function preservation</measure>
    <time_frame>post operative 48 hours later,1 week later, and 12 weeks later</time_frame>
    <description>Change of serum AMH from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of ovary</measure>
    <time_frame>post operative 48 hours later,1 week later, and 12 weeks later</time_frame>
    <description>ovarian volume measured by ultrasonography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Ovarian Cyst Benign</condition>
  <arm_group>
    <arm_group_label>SurgiGuard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar electrocauterization</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Bipolar electrocauterization during surgery Drug(-)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surgiguard</intervention_name>
    <description>Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy</description>
    <arm_group_label>SurgiGuard</arm_group_label>
    <other_name>laparoscopic unilateral ovarian cystectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 18 years ≤ Ages &lt;45 years

          -  laparoscopic unilateral ovarian cystectomy scheduled patients with benign unilateral
             ovarian cyst confirmed by ultrasonography

          -  women with regular menstruation

          -  women with regular menstruation cycle from 21 days to 45 days

          -  Proper state for laparoscopic operation (American society of Anesthesiologists
             Physical Status classification 1 or 2)

          -  Patients who signed and approved informed consent

        Exclusion Criteria:

          -  Patients without ovarian cyst

          -  Patients with malignant female genital disease

          -  Patients with bilateral ovarian cysts

          -  Age ≥ 45

          -  Pregnancy or lactating women

          -  Serum AMH&lt;0.05 ng/ml

          -  Patients with endocrine disease such as thyroid abnormality, hyperprolactinemia,
             cushing disease, etc

          -  Patients with hormone replacement therapy during 3 months

          -  Patients who is considered to be difficult to perform the clinical trial when
             researchers judge
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee Seung Kim, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>December 7, 2019</last_update_submitted>
  <last_update_submitted_qc>December 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee Seung Kim</investigator_full_name>
    <investigator_title>Associate Professor, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>Laparoscopic unilateral ovarian cystectomy</keyword>
  <keyword>SurgiGuard</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Ovarian function preservation</keyword>
  <keyword>Bipolar electrocauterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

